Hebei Changshan Biochem Pharma Total Assets
Hebei Changshan Biochem Pharma total assets. Based on the latest financial reports, Hebei Changshan Biochem Pharma (300255) holds total assets worth CN¥4.66 Billion CNY (≈ $681.55 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Hebei Changshan Biochem Pharma stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Hebei Changshan Biochem Pharma (2008–2024)
Total assets of Hebei Changshan Biochem Pharma from 2008 to 2024. This chart illustrates how Hebei Changshan Biochem Pharma's total assets have evolved over time, based on quarterly financial data. See Hebei Changshan Biochem Pharma stock quote for real-time trading data and today's change.
Hebei Changshan Biochem Pharma - Asset Composition Analysis
Hebei Changshan Biochem Pharma Total Assets Breakdown (December 2024)
Hebei Changshan Biochem Pharma total assets breakdown as of December 2024. Hebei Changshan Biochem Pharma's total assets of CN¥4.66 Billion consist of 44.3% current assets and 55.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 5.2% |
| Accounts Receivable | CN¥277.20 Million | 6.1% |
| Inventory | CN¥1.39 Billion | 30.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥735.99 Million | 16.3% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Hebei Changshan Biochem Pharma's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Hebei Changshan Biochem Pharma's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hebei Changshan Biochem Pharma's current assets represent 44.3% of total assets in 2024, a decrease from 61.7% in 2008.
- Cash Position: Cash and equivalents constituted 5.2% of total assets in 2024, up from 0.7% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 16.0% of total assets, an increase from 14.0% in 2008.
- Asset Diversification: The largest asset category is inventory at 30.6% of total assets.
Hebei Changshan Biochem Pharma Competitors by Total Assets
Key competitors of Hebei Changshan Biochem Pharma based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
Hebei Changshan Biochem Pharma - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.87 | 1.13 | 2.12 |
| Quick Ratio | 0.31 | 0.40 | 0.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-307.14 Million | CN¥266.05 Million | CN¥1.59 Billion |
Hebei Changshan Biochem Pharma - Advanced Valuation Insights
This section examines the relationship between Hebei Changshan Biochem Pharma's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 41.39 |
| Latest Market Cap to Assets Ratio | 0.59 |
| Asset Growth Rate (YoY) | -1.6% |
| Total Assets | CN¥4.52 Billion |
| Market Capitalization | $2.69 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Hebei Changshan Biochem Pharma's assets below their book value (0.59x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Hebei Changshan Biochem Pharma's assets decreased by 1.6% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Hebei Changshan Biochem Pharma (2008–2024)
The table below shows the annual total assets of Hebei Changshan Biochem Pharma from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.52 Billion ≈ $661.82 Million |
-1.60% |
| 2023-12-31 | CN¥4.60 Billion ≈ $672.61 Million |
-23.85% |
| 2022-12-31 | CN¥6.04 Billion ≈ $883.23 Million |
+16.30% |
| 2021-12-31 | CN¥5.19 Billion ≈ $759.44 Million |
+13.50% |
| 2020-12-31 | CN¥4.57 Billion ≈ $669.11 Million |
+15.98% |
| 2019-12-31 | CN¥3.94 Billion ≈ $576.93 Million |
+2.54% |
| 2018-12-31 | CN¥3.84 Billion ≈ $562.62 Million |
+8.92% |
| 2017-12-31 | CN¥3.53 Billion ≈ $516.56 Million |
+12.71% |
| 2016-12-31 | CN¥3.13 Billion ≈ $458.31 Million |
+34.52% |
| 2015-12-31 | CN¥2.33 Billion ≈ $340.70 Million |
+13.87% |
| 2014-12-31 | CN¥2.04 Billion ≈ $299.21 Million |
+24.28% |
| 2013-12-31 | CN¥1.65 Billion ≈ $240.76 Million |
+15.99% |
| 2012-12-31 | CN¥1.42 Billion ≈ $207.56 Million |
+19.58% |
| 2011-12-31 | CN¥1.19 Billion ≈ $173.58 Million |
+175.46% |
| 2010-12-31 | CN¥430.64 Million ≈ $63.02 Million |
+61.68% |
| 2009-12-31 | CN¥266.35 Million ≈ $38.98 Million |
+35.48% |
| 2008-12-31 | CN¥196.59 Million ≈ $28.77 Million |
-- |
About Hebei Changshan Biochem Pharma
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of crude heparin, heparin raw materials, and heparin preparations for the treatment of cardiovascular and cerebrovascular diseases in China and internationally. The company offers crude heparin sodium, heparin sodium API, heparin sodium injections, low molecular weight heparin calcium i… Read more